Press Trust of India on MSN
WuXi Biologics and HanchorBio enter strategic partnership to advance next-generation bi- and multi-functional fusion protein pipeline
SHANGHAI, Jan ...
Two recent, seemingly unrelated corporate maneuvers offer a telling glimpse into the strategic pivots major Chinese companies are making in response to shifting consumer habits and global political ...
Forbes contributors publish independent expert analyses and insights. I am the CIO of KraneShares, a China-focused ETF provider. Asian equities were mixed overnight as Mainland China's STAR Market and ...
China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...
HONG KONG, Aug. 19, 2025 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing ...
Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing ...
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 ...
China's WuXi group is on roll. Three leading firms in the drug services family are all coasting to bigger half-year profits, raising investor hopes of a sustained sectoral upswing. The WuXi trio ...
Mr. Dreyer is an American editor and writer who lives in Shanghai. Just outside Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and ...
SK Hynix has reportedly finished converting its key DRAM production facility in Wuxi, China, to the fourth-generation 1a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results